Bio-Techne Corporation Logo

Bio-Techne Corporation

TECH

(2.5)
Stock Price

74,89 USD

12.61% ROA

7.36% ROE

69.25x PER

Market Cap.

11.698.482.300,00 USD

16.04% DER

0.43% Yield

12.86% NPM

Bio-Techne Corporation Stock Analysis

Bio-Techne Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bio-Techne Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bio-Techne Corporation Price Chart

Chart

Combination chart with 3 data series.
The chart has 2 X axes displaying Time, and navigator-x-axis.
The chart has 3 Y axes displaying values, values, and navigator-y-axis.
View 1 month1mView 3 months3mView 6 months6mView year to dateYTDView 1 year1yView allAllHighcharts.com
End of interactive chart.

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bio-Techne Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
7.34
Net Income per Share
1.06
Price to Earning Ratio
69.25x
Price To Sales Ratio
10.09x
POCF Ratio
38.94
PFCF Ratio
49.55
Price to Book Ratio
5.63
EV to Sales
10.32
EV Over EBITDA
33.59
EV to Operating CashFlow
40.02
EV to FreeCashFlow
50.68
Earnings Yield
0.01
FreeCashFlow Yield
0.02
Market Cap
11,70 Bil.
Enterprise Value
11,97 Bil.
Graham Number
17.72
Graham NetNet
-2.03

Income Statement Metrics

Net Income per Share
1.06
Income Quality
1.78
ROE
0.08
Return On Assets
0.06
Return On Capital Employed
0.09
Net Income per EBT
0.85
EBT Per Ebit
0.77
Ebit per Revenue
0.2
Effective Tax Rate
0.15

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.08
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.66
Operating Profit Margin
0.2
Pretax Profit Margin
0.15
Net Profit Margin
0.13

Dividends

Dividend Yield
0
Dividend Yield %
0.43
Payout Ratio
0.3
Dividend Per Share
0.32

Operating Metrics

Operating Cashflow per Share
1.89
Free CashFlow per Share
1.5
Capex to Operating CashFlow
0.21
Capex to Revenue
0.05
Capex to Depreciation
0.56
Return on Invested Capital
0.09
Return on Tangible Assets
0.13
Days Sales Outstanding
76.02
Days Payables Outstanding
35.79
Days of Inventory on Hand
169.44
Receivables Turnover
4.8
Payables Turnover
10.2
Inventory Turnover
2.15
Capex per Share
0.4

Balance Sheet

Cash per Share
0,97
Book Value per Share
13,10
Tangible Book Value per Share
3.73
Shareholders Equity per Share
13.1
Interest Debt per Share
2.2
Debt to Equity
0.16
Debt to Assets
0.12
Net Debt to EBITDA
0.75
Current Ratio
3.87
Tangible Asset Value
0,59 Bil.
Net Current Asset Value
-0,13 Bil.
Invested Capital
2280223000
Working Capital
0,46 Bil.
Intangibles to Total Assets
0.53
Average Receivables
0,23 Bil.
Average Payables
0,03 Bil.
Average Inventory
179613500
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bio-Techne Corporation Profile

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

CEO
Mr. Kim Kelderman
Employee
3.100
Address
614 McKinley Place N.E.
Minneapolis, 55413

Bio-Techne Corporation Executives & BODs

Bio-Techne Corporation Competitors

BioMarin Pharmaceutical Inc. Logo
BioMarin Pharmaceutical Inc.

BMRN

(2.8)
Vaxcyte, Inc. Logo
Vaxcyte, Inc.

PCVX

(0.8)
Liquidia Corporation Logo
Liquidia Corporation

LQDA

(1.8)
Legend Biotech Corporation Logo
Legend Biotech Corporation

LEGN

(2.2)
Seagen Inc. Logo
Seagen Inc.

SGEN

(0.8)
Alnylam Pharmaceuticals, Inc. Logo
Alnylam Pharmaceuticals, Inc.

ALNY

(2.0)
Exelixis, Inc. Logo
Exelixis, Inc.

EXEL

(2.5)
Halozyme Therapeutics, Inc. Logo
Halozyme Therapeutics, Inc.

HALO

(2.2)
Replimune Group, Inc. Logo
Replimune Group, Inc.

REPL

(1.0)
Nuvalent, Inc. Logo
Nuvalent, Inc.

NUVL

(0.5)
Ventyx Biosciences, Inc. Logo
Ventyx Biosciences, Inc.

VTYX

(1.2)
Ascendis Pharma A/S Logo
Ascendis Pharma A/S

ASND

(0.0)
United Therapeutics Corporation Logo
United Therapeutics Corporation

UTHR

(3.0)
Apellis Pharmaceuticals, Inc. Logo
Apellis Pharmaceuticals, Inc.

APLS

(1.0)
BeiGene, Ltd. Logo
BeiGene, Ltd.

BGNE

(0.5)
Akero Therapeutics, Inc. Logo
Akero Therapeutics, Inc.

AKRO

(1.2)
Blueprint Medicines Corporation Logo
Blueprint Medicines Corporation

BPMC

(0.8)
Travere Therapeutics, Inc. Logo
Travere Therapeutics, Inc.

TVTX

(0.2)